Viral Vectors, Nucleic Acids, Cell Line, Antibodies, Consulting
Total Trials
21
As Lead Sponsor
18
As Collaborator
3
Total Enrollment
1,577
NCT04386967
OH2 Injection in Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 22, 2018
Completion: Dec 13, 2026
NCT03866525
OH2 Oncolytic Viral Therapy in Solid Tumors
Start: Apr 2, 2019
Completion: Aug 30, 2025
NCT05565014
Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Phase: Early Phase 1
Role: Collaborator
Start: Jul 24, 2020
Completion: Jun 30, 2024
NCT04616443
OH2 Injection in Combination With HX008 for Melanoma.
Start: Dec 1, 2020
Completion: Nov 30, 2025
NCT04637698
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Start: Feb 2, 2021
Completion: May 4, 2023
NCT05235074
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
Start: Nov 16, 2021
Completion: Jun 16, 2026
NCT05248789
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer
Phase: Phase 2
Start: May 25, 2022
Completion: Oct 28, 2024
NCT05232136
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
Start: Jul 11, 2022
Completion: Oct 31, 2025
NCT05716347
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Start: Jul 13, 2022
Completion: Sep 13, 2023
NCT05491421
A Study of ZT002 in Healthy Participants
Phase: Phase 1
Start: Sep 2, 2022
Completion: Apr 14, 2024
NCT05393440
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
Start: Sep 16, 2022
Completion: Jul 1, 2024
NCT05868707
OH2 Injection in Melanoma
Phase: Phase 3
Start: Mar 8, 2023
Completion: Mar 31, 2027
NCT05698459
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
Start: May 5, 2023
Completion: Jan 31, 2026
NCT06423872
A SAD Study of ZT002 Injection in Healthy Participants
Start: Jun 19, 2023
Completion: Dec 8, 2023
NCT05648006
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
Start: Oct 17, 2023
Completion: Apr 15, 2024
NCT06371326
A Study of ZT002 Injection in Participants With Overweight or Obesity
Start: Nov 21, 2023
Completion: Sep 30, 2024
NCT05938296
OHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Start: Dec 19, 2023
Completion: Jan 1, 2026
NCT07065032
A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
Start: Feb 19, 2024
Completion: Aug 5, 2024
NCT07020884
A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity
Start: Aug 14, 2024
Completion: Dec 30, 2025
NCT05954091
OH2 Administered by Intratumoral Injection
Start: Sep 1, 2025
Completion: Jan 1, 2028
NCT07184502
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
Start: Oct 9, 2025
Completion: Oct 10, 2026
Loading map...